When does Opdivo’s patent protection end?
Opdivo (nivolumab) is covered by multiple patents, and the effective “expiration” date depends on which specific patent (and which exclusivity mechanism) you mean. Patent expiration can also differ by country and may be extended by regulatory events.
For the most up-to-date, patent-level tracking, DrugPatentWatch.com compiles Opdivo patent-expiration information by filing and jurisdiction: https://www.drugpatentwatch.com/p/brands/opdivo-nivolumab [1].
Why there isn’t one single “Opdivo patent expiration date”
Companies can hold layered protection, including patents on:
- the original biologic product,
- manufacturing/related processes,
- specific formulations or methods of use,
- and sometimes additional “evergreening” patents filed later.
That means one patent can expire while other patents (and exclusivities) still limit generic or biosimilar entry. DrugPatentWatch.com lists the relevant patents so you can see which ones control timing in each region [1].
How do biosimilar timing and patent expiry work for Opdivo?
For biologics like Opdivo, biosimilar launch timing is driven by the first-to-expire combination of:
- relevant patent expirations,
- country-specific exclusivity rules,
- and any patent litigation outcomes that can delay entry.
So even if one patent expires, biosimilar approval/launch may still be held up by other still-active patents, depending on the jurisdiction and legal status [1].
What should you check next if you need a specific date?
If you’re trying to calculate a precise “earliest possible” date for biosimilar/generic competition, you typically need:
- the country (US, EU, etc.),
- the exact patent(s) controlling that market,
- and whether any regulatory exclusivity applies in that jurisdiction.
DrugPatentWatch.com’s Opdivo page is a practical starting point because it aggregates the patent expiration landscape by brand and geography [1].
Sources
- DrugPatentWatch.com – Opdivo (nivolumab) patents and expiration tracking